Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
FOLLISTIM AQ is a recombinant follicle-stimulating hormone (FSH) used to stimulate ovarian follicle development in assisted reproductive technology (ART) and infertility treatment. Administered via subcutaneous injection, it mimics the body's natural FSH to promote multiple follicle maturation in women undergoing fertility procedures. The product has been a cornerstone of ovarian stimulation protocols since its 2005 approval.
Approaching loss of exclusivity signals contraction phase; commercial teams face biosimilar competition and market consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on FOLLISTIM AQ offers solid experience in specialty pharmaceutical management within a therapeutic niche with loyal clinical advocates and stable patient demand. However, approaching LOE limits growth trajectory; career value lies in managing competitive transition, reimbursement strategy, and potential biosimilar portfolio integration.
Worked on FOLLISTIM AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.